CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Positron Emission Tomography–Computed Tomography versus Magnetic Resonance Imaging for Adult Patients with Suspected Cardiac Sarcoidosis: Clinical Utility, Cost-Effectiveness, and Diagnostic Accuracy

Last updated: September 28, 2020
Project Number: RA1139-000
Product Line: Rapid Response
Research Type: Device
Report Type: Reference List
Result type: Report

Question

  1. What is the clinical utility of positron emission tomography–computed tomography compared to magnetic resonance imaging in patients with suspected active cardiac sarcoidosis?
  2. What is the cost-effectiveness of positron emission tomography–computed tomography compared to magnetic resonance imaging in patients with suspected active cardiac sarcoidosis?
  3. What is the diagnostic accuracy of positron emission tomography–computed tomography in patients with suspected active cardiac sarcoidosis?

Key Message

One non-randomized study was identified regarding the clinical utility of positron emission tomography–computed tomography compared to magnetic resonance imaging in patients with suspected active cardiac sarcoidosis. Furthermore, two systematic reviews with meta-analysis and eight non-randomized studies were identified regarding the diagnostic accuracy of positron emission tomography–computed tomography in patients with suspected active cardiac sarcoidosis. No relevant literature was identified regarding the cost-effectiveness of positron emission tomography–computed tomography compared to magnetic resonance imaging in patients with suspected active cardiac sarcoidosis.